Sanofi keeps foot on the gas, agree­ing to five-year col­lab­o­ra­tion with MD An­der­son

5 years ago
Deals

Cy­to­ki­net­ics nabs Chi­nese part­ner, up to $450M as CV be­comes com­pa­ny fo­cus

5 years ago
R&D

Bil­lions of dol­lars worth of SPACs are rid­ing on the biotech IPO boom

5 years ago
Financing

FDA re­jects Ver­ri­ca’s skin warts pitch, a month af­ter flag­ging ap­pli­ca­tion ‘de­fi­cien­cies’

5 years ago
FDA+

A neoanti­gen pi­o­neer says its tech is work­ing great. So what wrecked the share price?

5 years ago
Bioregnum
Opinion

Covid-19 roundup: Af­ter Trump at­tack, doc­tors, re­searchers flock to de­fend Fau­ci; Philip Mor­ris-backed Med­ica­go ...

5 years ago
Coronavirus

More Warp Speed con­tracts com­ing, vac­cine pro­duc­tion to be­gin in 4-6 weeks — of­fi­cials

5 years ago
Coronavirus

Di­ag­nos­tic champ Roche buys its way in­to the RET ti­tle fight with Eli Lil­ly, pay­ing $775M in cash to Blue­print

5 years ago
Deals

Mass­a­chu­setts biotech Re­vi­tope scores first col­lab­o­ra­tion thanks to dual-en­gag­ing T cell plat­form

5 years ago
Deals

Cel­sion takes a nose­dive as board rec­om­mends tri­al halt; Three biotech IPOs set terms above $90M

5 years ago
News Briefing

Cy­to­Dyn shares slammed as BLA fil­ing for leron­limab in HIV hits a wall

5 years ago
FDA+

En­gi­neer­ing an on/off switch for CAR-T out of yeast and Juras­sic Park

5 years ago
R&D
Cell/Gene Tx

White House tries to dis­cred­it An­tho­ny Fau­ci — could he be on his way out?

5 years ago
People
Coronavirus

Play­ing catch-up, Roche out­lines plans for a PhI­II he­mo­phil­ia A pro­gram — next year

5 years ago
R&D
Cell/Gene Tx

A top an­a­lyst turns the spot­light on Mod­er­na, fu­el­ing a fast-and-fu­ri­ous Street race over the fu­ture of mR­NA

5 years ago
Bioregnum
Coronavirus

Covid-19 roundup: CanSi­no eyes more over­seas PhI­II sites as Cana­da tri­al re­port­ed­ly stalls; In­di­an drug­mak­er surges ...

5 years ago
R&D
Coronavirus

Chi­na's BeiGene now has $5B+ cash in its cof­fers. How's the Am­gen-part­nered biotech go­ing to spend it?

5 years ago
China

Roche’s PD-L1 play­er Tecen­triq fails PhI­II for ovar­i­an can­cer

5 years ago
R&D

Two years af­ter a ‘pos­i­tive’ re­sult tanked their stock, Ovid's Je­re­my Levin wins a part­ner for the PhI­II jour­ney

5 years ago
Deals
R&D

Af­ter go­ing ‘crazy’ over the sci­ence, Mer­ck signs up a new part­ner in the hunt for an HIV cure

5 years ago
Deals

An­oth­er four biotechs scratch out the first num­ber and ask for more as IPO boom con­tin­ues

5 years ago
Financing

As­traZeneca signs com­pu­ta­tion­al drug dis­cov­ery col­lab­o­ra­tion; J&J-part­nered Fate cleared for the clin­ic

5 years ago
News Briefing

Top biotech an­a­lyst projects a gloomy out­look for Pfiz­er's JAK port­fo­lio

5 years ago
Pharma

Oph­thalmic drugs, can­cer cell ther­a­pies at­tract $340M+ on two HKEX biotech de­buts

5 years ago
Financing
China
First page Previous page 823824825826827828829 Next page Last page
A service from the Financial Times